CRISPR Therapeutics AG (CRSP) Depreciation & Amortization (CF) (2015 - 2026)

CRISPR Therapeutics AG has disclosed Depreciation & Amortization (CF) across 12 years of filings, most recently posting $4.3 million for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $4.3 million, down 8.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.1 million (down 0.52% YoY), and the FY2025 annual result was $19.5 million, up 1.14% from the prior year.
• Depreciation & Amortization (CF) came in at $4.3 million for Q1 2026 at CRISPR Therapeutics AG, down from $5.7 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $7.3 million in Q2 2022 to a low of $4.3 million in Q1 2026.
• The 5-year median for Depreciation & Amortization (CF) is $4.9 million (2023), against an average of $5.1 million.
• Across the five-year window, Depreciation & Amortization (CF) jumped 122.43% in 2022 and tumbled 31.75% in 2023, its largest moves.
• CRISPR Therapeutics AG's Depreciation & Amortization (CF) stood at $5.8 million in 2022, then declined by 16.18% to $4.9 million in 2023, then slipped by 1.18% to $4.8 million in 2024, then rose by 16.91% to $5.7 million in 2025, then retreated by 23.71% to $4.3 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $4.3 million (Q1 2026), $5.7 million (Q4 2025), and $4.4 million (Q3 2025), per Business Quant data.